drugset / Trial / NCT02722941
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
Phase 2
Completed
30 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant (HCT).
Timeline
- Start
- 2016-06-10
- Primary completion
- 2020-06-07
- Completion
- 2021-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Panobinostat | Small molecule | 10 mg | Oral |
| Comparator | Panobinostat | Small molecule | 20 mg | Oral |